| Features: |
| Resiquimod is a synthetic compound that acts as an immune response modifier. It is a toll-like receptor 7 and 8 (TLR7/8) agonist, which means it activates these receptors on immune cells, such as dendritic cells and macrophages. |
| Source: |
| Type: |
| Caspase-9 is the apoptotic initiator protease of the intrinsic or mitochondrial apoptotic pathway, which is activated at multi-protein activation platforms. Caspases are divided into two groups: the initiator caspases (caspase-2, -8, -9 and -10), which are the first to be activated in response to a signal, and the executioner caspases (caspase-3, -6, and -7) that carry out the demolition phase of apoptosis. Caspase-9: Role: Initiator caspase in the intrinsic apoptotic pathway. Cancers: Frequently studied in leukemia and solid tumors. Prognosis: Reduced expression is often linked to chemoresistance and poor prognosis. |
| 346- | AgNPs, | RSQ, | Investigating Silver Nanoparticles and Resiquimod as a Local Melanoma Treatment |
| - | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vivo, | Melanoma, | WM35 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:208 Target#:45 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid